ReviewFrontiers in cell and developmental biology2026
Mesenchymal stem cell and exosome-based therapies for degenerative disc disease: from mechanisms to clinical translation.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative disc disease (DDD) is a leading cause of chronic low back pain and disability worldwide, placing a significant burden on public health systems and economies. The pathogenesis of DDD is characterized by oxidative stress, chronic inflammation, dysregulated cell death, and impaired extracellular matrix (ECM) homeostasis, all of which contribute to the structural degradation and functional impairment of intervertebral discs. Current clinical treatments primarily offer palliative relief, underscoring the urgent need for regenerative therapies that address the underlying pathological mechanisms. Mesenchymal stem cells (MSCs) and their exosomes (Exos) have emerged as promising candidates for DDD therapy, as they stimulate ECM synthesis, regulate inflammation, and enhance cell survival. Furthermore, advanced biomaterials have been developed to create bioactive environments that enhance cell retention and facilitate controlled therapeutic delivery. This review provides a comprehensive overview of the molecular mechanisms driving DDD, evaluates MSC/Exo and biomaterial-based therapies, and explores emerging technologies for personalized treatment strategies aimed at restoring disc function, extending beyond symptomatic management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.